Cannabis - Revision history

Lazy at 08:19, 18 January 2025

2025-01-18T08:19:43Z

← Older revision		Revision as of 01:19, 18 January 2025
Line 14:		Line 14:
	\|toxicity_level=1		\|toxicity_level=1
	\|toxicity_explanation=The treatment mentioned, Cannabis and Cannabis-derived products like Sativex, generally have minimal side effects. These may include dry mouth, red eyes, and increased appetite, causing mild discomfort rather than serious complications. Therefore, the toxicity is considered low (rated 1 out of 5), meaning it's generally safe with a low risk of harm. However, please note that all individuals may respond differently, and it's important to discuss any new treatments with your healthcare provider.		\|toxicity_explanation=The treatment mentioned, Cannabis and Cannabis-derived products like Sativex, generally have minimal side effects. These may include dry mouth, red eyes, and increased appetite, causing mild discomfort rather than serious complications. Therefore, the toxicity is considered low (rated 1 out of 5), meaning it's generally safe with a low risk of harm. However, please note that all individuals may respond differently, and it's important to discuss any new treatments with your healthcare provider.
	}}		\|overview=Cannabis and cannabis-derived products, such as Sativex, are being investigated for their potential use in cancer treatment, particularly glioblastoma, where clinical trials have shown promising results in extending median survival when combined with temozolomide. While Sativex is approved in Canada and Europe for neuropathic pain, cannabis itself is not FDA-approved for cancer treatment, though it is noted for its low toxicity and minimal side effects.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:29:17Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:29, 12 November 2024
Line 10:		Line 10:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=In a Phase 2 clinical trial conducted in 2021, Sativex in combination with temozolomide showed promising results for recurrent glioblastoma patients, significantly extending median survival compared to temozolomide alone. This trial underscores the potential of cannabis-based products, like Sativex, as adjunct therapies in cancer treatment, particularly in glioblastoma. These results mark a critical step forward in cannabis research within oncology, warranting further investigation to establish comprehensive benefits and usage protocols.		\|notes=In a Phase 2 clinical trial conducted in 2021, Sativex in combination with temozolomide showed promising results for recurrent glioblastoma patients, significantly extending median survival compared to temozolomide alone. This trial underscores the potential of cannabis-based products, like Sativex, as adjunct therapies in cancer treatment, particularly in glioblastoma. These results mark a critical step forward in cannabis research within oncology, warranting further investigation to establish comprehensive benefits and usage protocols.
	\|~~category~~=Nutraceuticals		\|treatment_category=Nutraceuticals
	\|links=		\|links=
	\|toxicity_level=1		\|toxicity_level=1
	\|toxicity_explanation=The treatment mentioned, Cannabis and Cannabis-derived products like Sativex, generally have minimal side effects. These may include dry mouth, red eyes, and increased appetite, causing mild discomfort rather than serious complications. Therefore, the toxicity is considered low (rated 1 out of 5), meaning it's generally safe with a low risk of harm. However, please note that all individuals may respond differently, and it's important to discuss any new treatments with your healthcare provider.		\|toxicity_explanation=The treatment mentioned, Cannabis and Cannabis-derived products like Sativex, generally have minimal side effects. These may include dry mouth, red eyes, and increased appetite, causing mild discomfort rather than serious complications. Therefore, the toxicity is considered low (rated 1 out of 5), meaning it's generally safe with a low risk of harm. However, please note that all individuals may respond differently, and it's important to discuss any new treatments with your healthcare provider.
	}}		}}

Lazy at 18:06, 27 March 2024

2024-03-27T18:06:46Z

← Older revision		Revision as of 11:06, 27 March 2024
Line 10:		Line 10:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=In a Phase 2 clinical trial conducted in 2021, Sativex in combination with temozolomide showed promising results for recurrent glioblastoma patients, significantly extending median survival compared to temozolomide alone. This trial underscores the potential of cannabis-based products, like Sativex, as adjunct therapies in cancer treatment, particularly in glioblastoma. These results mark a critical step forward in cannabis research within oncology, warranting further investigation to establish comprehensive benefits and usage protocols.		\|notes=In a Phase 2 clinical trial conducted in 2021, Sativex in combination with temozolomide showed promising results for recurrent glioblastoma patients, significantly extending median survival compared to temozolomide alone. This trial underscores the potential of cannabis-based products, like Sativex, as adjunct therapies in cancer treatment, particularly in glioblastoma. These results mark a critical step forward in cannabis research within oncology, warranting further investigation to establish comprehensive benefits and usage protocols.
	\|category=Nutraceuticals ~~and herbals~~		\|category=Nutraceuticals
	\|links=		\|links=
	\|toxicity_level=1		\|toxicity_level=1
	\|toxicity_explanation=The treatment mentioned, Cannabis and Cannabis-derived products like Sativex, generally have minimal side effects. These may include dry mouth, red eyes, and increased appetite, causing mild discomfort rather than serious complications. Therefore, the toxicity is considered low (rated 1 out of 5), meaning it's generally safe with a low risk of harm. However, please note that all individuals may respond differently, and it's important to discuss any new treatments with your healthcare provider.		\|toxicity_explanation=The treatment mentioned, Cannabis and Cannabis-derived products like Sativex, generally have minimal side effects. These may include dry mouth, red eyes, and increased appetite, causing mild discomfort rather than serious complications. Therefore, the toxicity is considered low (rated 1 out of 5), meaning it's generally safe with a low risk of harm. However, please note that all individuals may respond differently, and it's important to discuss any new treatments with your healthcare provider.
	}}		}}

Lazy at 16:54, 27 March 2024

2024-03-27T16:54:34Z

← Older revision		Revision as of 09:54, 27 March 2024
Line 12:		Line 12:
	\|category=Nutraceuticals and herbals		\|category=Nutraceuticals and herbals
	\|links=		\|links=
			\|toxicity_level=1
			\|toxicity_explanation=The treatment mentioned, Cannabis and Cannabis-derived products like Sativex, generally have minimal side effects. These may include dry mouth, red eyes, and increased appetite, causing mild discomfort rather than serious complications. Therefore, the toxicity is considered low (rated 1 out of 5), meaning it's generally safe with a low risk of harm. However, please note that all individuals may respond differently, and it's important to discuss any new treatments with your healthcare provider.
	}}		}}

Lazy at 12:21, 21 March 2024

2024-03-21T12:21:25Z

← Older revision		Revision as of 05:21, 21 March 2024
Line 3:		Line 3:
	\|FDA_approval=Sativex is approved in Canada and some European countries for neuropathic pain; cannabis itself is not FDA-approved for cancer treatment		\|FDA_approval=Sativex is approved in Canada and some European countries for neuropathic pain; cannabis itself is not FDA-approved for cancer treatment
	\|used_for=Investigational use in cancer treatment, including glioblastoma, for its direct anti-cancer and anti-nausea effects		\|used_for=Investigational use in cancer treatment, including glioblastoma, for its direct anti-cancer and anti-nausea effects
	\|clinical_trial_phase=~~Preclinical studies and early clinical trials, including a notable~~ trial with Sativex ~~for glioblastoma~~		\|clinical_trial_phase=Phase 2 trial for glioblastoma with Sativex combined with temozolomide
	\|common_side_effects=Varies; cannabis is known for minimal side effects such as dry mouth, red eyes, and increased appetite. Sativex may have additional side effects similar to other cannabis products.		\|common_side_effects=Varies; cannabis is known for minimal side effects such as dry mouth, red eyes, and increased appetite. Sativex may have additional side effects similar to other cannabis products.
	\|OS_without=Dose-intense temozolomide alone: Median survival from trial start was 369 days (12.1 months)		\|OS_without=Dose-intense temozolomide alone: Median survival from trial start was 369 days (12.1 months)
Line 9:		Line 9:
	\|PFS_with=Not specifically mentioned; research primarily focused on overall survival and symptomatic relief		\|PFS_with=Not specifically mentioned; research primarily focused on overall survival and symptomatic relief
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=~~Recent research on cannabis and its derivatives, like Sativex, has explored their anti-cancer potential, with studies indicating their ability to inhibit glioma growth and angiogenesis. A~~ clinical trial ~~with~~ Sativex in combination with temozolomide for recurrent glioblastoma patients ~~demonstrated a significant~~ survival ~~benefit, suggesting~~ the ~~therapeutic promise~~ of cannabis-based products in cancer treatment. ~~This advancement underscores the necessity of~~ further ~~clinical trials~~ to ~~confirm the efficacy~~ and ~~explore the broader applications of cannabis in oncology~~.		\|notes=In a Phase 2 clinical trial conducted in 2021, Sativex in combination with temozolomide showed promising results for recurrent glioblastoma patients, significantly extending median survival compared to temozolomide alone. This trial underscores the potential of cannabis-based products, like Sativex, as adjunct therapies in cancer treatment, particularly in glioblastoma. These results mark a critical step forward in cannabis research within oncology, warranting further investigation to establish comprehensive benefits and usage protocols.
	\|category=Nutraceuticals and herbals		\|category=Nutraceuticals and herbals
	\|links=		\|links=
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Cannabis and Cannabis-derived Products (e.g., Sativex) |FDA_approval=Sativex is approved in Canada and some European countries for neuropathic pain; cannabis itself is not FDA-approved for cancer treatment |used_for=Investigational use in cancer treatment, including glioblastoma, for its direct anti-cancer and anti-nausea effects |clinical_trial_phase=Preclinical studies and early clinical trials, including a notable trial with Sativex for glio..."

2024-03-21T12:18:43Z

Created page with "{{TreatmentInfo |drug_name=Cannabis and Cannabis-derived Products (e.g., Sativex) |FDA_approval=Sativex is approved in Canada and some European countries for neuropathic pain; cannabis itself is not FDA-approved for cancer treatment |used_for=Investigational use in cancer treatment, including glioblastoma, for its direct anti-cancer and anti-nausea effects |clinical_trial_phase=Preclinical studies and early clinical trials, including a notable trial with Sativex for glio..."

New page

{{TreatmentInfo
|drug_name=Cannabis and Cannabis-derived Products (e.g., Sativex)
|FDA_approval=Sativex is approved in Canada and some European countries for neuropathic pain; cannabis itself is not FDA-approved for cancer treatment
|used_for=Investigational use in cancer treatment, including glioblastoma, for its direct anti-cancer and anti-nausea effects
|clinical_trial_phase=Preclinical studies and early clinical trials, including a notable trial with Sativex for glioblastoma
|common_side_effects=Varies; cannabis is known for minimal side effects such as dry mouth, red eyes, and increased appetite. Sativex may have additional side effects similar to other cannabis products.
|OS_without=Dose-intense temozolomide alone: Median survival from trial start was 369 days (12.1 months)
|OS_with=Sativex combined with dose-intense temozolomide: Median survival exceeded 550 days (over 18 months)
|PFS_with=Not specifically mentioned; research primarily focused on overall survival and symptomatic relief
|usefulness_rating=4
|notes=Recent research on cannabis and its derivatives, like Sativex, has explored their anti-cancer potential, with studies indicating their ability to inhibit glioma growth and angiogenesis. A clinical trial with Sativex in combination with temozolomide for recurrent glioblastoma patients demonstrated a significant survival benefit, suggesting the therapeutic promise of cannabis-based products in cancer treatment. This advancement underscores the necessity of further clinical trials to confirm the efficacy and explore the broader applications of cannabis in oncology.
|category=Nutraceuticals and herbals
|links=
}}